Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease

Young C. Chung, Jeong Y. Baek, Sang R. Kim, Hyuk W. Ko, Eugene Bok, Won Ho Shin, So Yoon Won, Byung K. Jin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The effects of capsaicin (CAP), a transient receptor potential vanilloid subtype 1 (TRPV1) agonist, were determined on nigrostriatal dopamine (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). The results showed that TRPV1 activation by CAP rescued nigrostriatal DA neurons, enhanced striatal DA functions and improved behavioral recovery in MPTP-treated mice. CAP neuroprotection was associated with reduced expression of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) and reactive oxygen species/reactive nitrogen species from activated microglia-derived NADPH oxidase, inducible nitric oxide synthase or reactive astrocyte-derived myeloidperoxidase. These beneficial effects of CAP were reversed by treatment with the TRPV1 antagonists capsazepine and iodo-resiniferatoxin, indicating TRPV1 involvement. This study demonstrates that TRPV1 activation by CAP protects nigrostriatal DA neurons via inhibition of glial activation-mediated oxidative stress and neuroinflammation in the MPTP mouse model of PD. These results suggest that CAP and its analogs may be beneficial therapeutic agents for the treatment of PD and other neurodegenerative disorders that are associated with neuroinflammation and glial activation-derived oxidative damage.

Original languageEnglish
Article numbere298
JournalExperimental and Molecular Medicine
Volume49
Issue number3
DOIs
Publication statusPublished - 2017 Mar 3

Fingerprint

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Oxidative stress
Dopaminergic Neurons
Capsaicin
Neuroglia
Neurons
Parkinson Disease
Dopamine
Oxidative Stress
Chemical activation
Corpus Striatum
Reactive Nitrogen Species
NADPH Oxidase
Microglia
Nitric Oxide Synthase Type II
Interleukin-1
Astrocytes
Neurodegenerative Diseases
Reactive Oxygen Species
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Chung, Young C. ; Baek, Jeong Y. ; Kim, Sang R. ; Ko, Hyuk W. ; Bok, Eugene ; Shin, Won Ho ; Won, So Yoon ; Jin, Byung K. / Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease. In: Experimental and Molecular Medicine. 2017 ; Vol. 49, No. 3.
@article{fc47025bfa11462fada5aaff58c4b54c,
title = "Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease",
abstract = "The effects of capsaicin (CAP), a transient receptor potential vanilloid subtype 1 (TRPV1) agonist, were determined on nigrostriatal dopamine (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). The results showed that TRPV1 activation by CAP rescued nigrostriatal DA neurons, enhanced striatal DA functions and improved behavioral recovery in MPTP-treated mice. CAP neuroprotection was associated with reduced expression of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) and reactive oxygen species/reactive nitrogen species from activated microglia-derived NADPH oxidase, inducible nitric oxide synthase or reactive astrocyte-derived myeloidperoxidase. These beneficial effects of CAP were reversed by treatment with the TRPV1 antagonists capsazepine and iodo-resiniferatoxin, indicating TRPV1 involvement. This study demonstrates that TRPV1 activation by CAP protects nigrostriatal DA neurons via inhibition of glial activation-mediated oxidative stress and neuroinflammation in the MPTP mouse model of PD. These results suggest that CAP and its analogs may be beneficial therapeutic agents for the treatment of PD and other neurodegenerative disorders that are associated with neuroinflammation and glial activation-derived oxidative damage.",
author = "Chung, {Young C.} and Baek, {Jeong Y.} and Kim, {Sang R.} and Ko, {Hyuk W.} and Eugene Bok and Shin, {Won Ho} and Won, {So Yoon} and Jin, {Byung K.}",
year = "2017",
month = "3",
day = "3",
doi = "10.1038/emm.2016.159",
language = "English",
volume = "49",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "3",

}

Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease. / Chung, Young C.; Baek, Jeong Y.; Kim, Sang R.; Ko, Hyuk W.; Bok, Eugene; Shin, Won Ho; Won, So Yoon; Jin, Byung K.

In: Experimental and Molecular Medicine, Vol. 49, No. 3, e298, 03.03.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease

AU - Chung, Young C.

AU - Baek, Jeong Y.

AU - Kim, Sang R.

AU - Ko, Hyuk W.

AU - Bok, Eugene

AU - Shin, Won Ho

AU - Won, So Yoon

AU - Jin, Byung K.

PY - 2017/3/3

Y1 - 2017/3/3

N2 - The effects of capsaicin (CAP), a transient receptor potential vanilloid subtype 1 (TRPV1) agonist, were determined on nigrostriatal dopamine (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). The results showed that TRPV1 activation by CAP rescued nigrostriatal DA neurons, enhanced striatal DA functions and improved behavioral recovery in MPTP-treated mice. CAP neuroprotection was associated with reduced expression of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) and reactive oxygen species/reactive nitrogen species from activated microglia-derived NADPH oxidase, inducible nitric oxide synthase or reactive astrocyte-derived myeloidperoxidase. These beneficial effects of CAP were reversed by treatment with the TRPV1 antagonists capsazepine and iodo-resiniferatoxin, indicating TRPV1 involvement. This study demonstrates that TRPV1 activation by CAP protects nigrostriatal DA neurons via inhibition of glial activation-mediated oxidative stress and neuroinflammation in the MPTP mouse model of PD. These results suggest that CAP and its analogs may be beneficial therapeutic agents for the treatment of PD and other neurodegenerative disorders that are associated with neuroinflammation and glial activation-derived oxidative damage.

AB - The effects of capsaicin (CAP), a transient receptor potential vanilloid subtype 1 (TRPV1) agonist, were determined on nigrostriatal dopamine (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). The results showed that TRPV1 activation by CAP rescued nigrostriatal DA neurons, enhanced striatal DA functions and improved behavioral recovery in MPTP-treated mice. CAP neuroprotection was associated with reduced expression of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) and reactive oxygen species/reactive nitrogen species from activated microglia-derived NADPH oxidase, inducible nitric oxide synthase or reactive astrocyte-derived myeloidperoxidase. These beneficial effects of CAP were reversed by treatment with the TRPV1 antagonists capsazepine and iodo-resiniferatoxin, indicating TRPV1 involvement. This study demonstrates that TRPV1 activation by CAP protects nigrostriatal DA neurons via inhibition of glial activation-mediated oxidative stress and neuroinflammation in the MPTP mouse model of PD. These results suggest that CAP and its analogs may be beneficial therapeutic agents for the treatment of PD and other neurodegenerative disorders that are associated with neuroinflammation and glial activation-derived oxidative damage.

UR - http://www.scopus.com/inward/record.url?scp=85014613713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014613713&partnerID=8YFLogxK

U2 - 10.1038/emm.2016.159

DO - 10.1038/emm.2016.159

M3 - Article

C2 - 28255166

AN - SCOPUS:85014613713

VL - 49

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 3

M1 - e298

ER -